Skip to main content
letter
. 2024 Feb 20;23:38. doi: 10.1186/s12943-024-01946-8

Fig. 1.

Fig. 1

Efficacy of JX-594 combined with low-dose cyclophosphamide and avelumab in patients with advanced “cold” sarcomas. (A) Waterfall plot of the maximum change in tumor size in 14 patients with sarcomas and eligible for efficacy analysis. (B-C) Kaplan–Meier curves associated with Progression-free survival (B) and overall survival (C). (D-I) Illustrations of tumor HES staining (D-G), tumor CD8 staining (E-H) and Computed Tomography scan (F-I) obtained from the patient with partial response at baseline (D-E-F) and C2D1(G-H-I)